GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (STU:SG7) » Definitions » Price-to-Funds-From-Operations

Sage Therapeutics (STU:SG7) Price-to-Funds-From-Operations : (As of Apr. 11, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Sage Therapeutics Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.